About Evogene

Evogene (NASDAQ:EVGN, TASE: EVGN.TA) is a leading computational biology company aiming to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications.

Incorporating a deep understanding of biology and leveraging Big Data and Artificial Intelligence, Evogene established its unique technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products.

Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production.

Evogene leverages its technology through:

Partnerships — Evogene engages with leading companies for joint development of defined products utilizing Evogene’s unique solution. Later-stage development and commercialization of the product will typically be done by the partner.

Subsidiaries — Evogene has established independent entities focusing on defined commercial fields, holding an exclusive license to use Evogene’s unique solutions for product development. The subsidiary may develop and commercialize products independently or through strategic collaborations.

    • Mr. Ofer Haviv

      Mr. Ofer Haviv

      President and Chief Executive Officer

      Mr. Ofer Haviv holds the position of Evogene’s President and CEO as of late 2004. Prior to that he held the positions of company COO and CFO from 2002 to 2004 and was involved in Evogene’s spin-off from Compugen in 2002. At Compugen, he held the position of Director of Finance and Treasurer of Compugen (NASDAQ: CGEN) for four years, during which time the company completed two private placements and an IPO on NASDAQ

      Mr. Haviv holds a B.A. degree in Economics and Accounting from Faculty of Management, Tel Aviv University and is a Certified Public Accountant in Israel.

      ofer.haviv@evogene.com

    • Ms. Dorit Kreiner

      Ms. Dorit Kreiner

      Chief Financial Officer

      Ms. Dorit Kreiner was appointed as CFO in February 2019, bringing over 20 years of senior financial management experience in both public and private companies. Most recently, Ms. Kreiner served as Chief Financial Officer of Therapix (TASE: THXBY) and NRGene. Previously, Ms. Kreiner served as Director of Finance of Evogene from June 2004 through August 2011.

      Ms. Kreiner holds a BA in Accounting and Economics from Tel Aviv University and she is a Certified Public Accountant in Israel. Additionally, Ms. Kreiner holds an MBA in Finance and Marketing from Tel Aviv University and a Bachelor of Law from the College of Management.

      Dorit.Kreiner@evogene.com

    • Mr. Gadi Ben Nissim

      Mr. Gadi Ben Nissim

      EVP Corporate Development

      Mr. Gadi Ben Nissim was appointed as EVP Corporate Development in May 2020, bringing over 20 years of versatile international experience within the pharmaceutical industry in both generics and specialty brands, across various geographies. He served as Executive VP, US Generics division at Mayne Pharma (ASX: MYX). Prior to that Gadi held various senior leadership positions at Teva Pharmaceuticals (NASDAQ: TEVA) including: VP Integration North America; VP strategy & commercial operations, Global Women’s Health; VP commercial operations and Head of Specialty Brands for Growth markets division, and Head of Generics business, Teva Israel.

      Mr. Ben-Nissim holds a B.S.c. in Industrial Engineering from the Technion, and MBA from the IDC.

      gadi.bennissim@evogene.com

    • Dr. Eyal Emmanuel

      Dr. Eyal Emmanuel

      Chief Scientific Officer

      Dr. Eyal Emmanuel serves as Evogene’s CSO since February 2019. Dr. Emmanuel rejoined Evogene as VP of Corporate Strategy in September 2018, previously held several R&D positions in the Company from May 2006 through October 2017, including Executive R&D Crop Protection and Chief Science Officer.

      Dr. Emmanuel holds a Ph.D. from the Weizmann Institute of Science, and an MBA from the College of Management.

      Eyal.Emmanuel@evogene.com

    • Mr. Mark Kapel

      Mr. Mark Kapel

      Executive Vice President Technology

      Mr. Kapel was appointed as Executive Vice President Technology in February 2018, previously serving as Director of Information Technologies & Data Management from 2013. Mr. Kapel joined Evogene in 2005 and has held various positions in the company over the years.

      Mr. Kapel holds a B.Sc. in Physics & Computers from the Ben Gurion University of Negev, an MBA majoring in Management of Technology from Tel Aviv University’s Faculty of Management – Recanati Graduate School of Business Administration.

      mark.kapel@evogene.com

    • Dr. Gaya Loren

      Dr. Gaya Loren

      Executive Vice President Product Development

      Dr. Gaya Loren has been appointed as Executive Vice President (EVP) Product Development of Evogene in 2020. Dr. Loren brings multidisciplinary expertise in innovation-driven ventures with over 20 years of managerial experience in early and mid-stage investments as well as research and development experience in the biotech and hi-tech industries. Dr. Loren previously served as Chief Technology Officer at Hutchison-Kinrot, a start-up incubator, where she screened, co-built and directed multiple startups. Prior to this Dr. Loren served as Core Technology Manager in Evogene during the years 2002-2004.
      Dr. Loren holds a PhD in Bioinformatics from the Hebrew University of Jerusalem.

      gaya.loren@evogene.com

    • Mr. Martin Gerstel, Chairman

      Chairman of the Board

      Mr. Martin S. Gerstel serves as the Chairman of the Board of Directors of Evogene since 2004, is a director and co-founder of Itamar Medical, a medical device company, and director of MazeBolt Technologies, a cyber security company.

      In addition, between 1997 and 2017, Mr. Gerstel served as the Chairman of the Board of Directors of Compugen Ltd., a predictive drug discovery and development company which was the parent company of Evogene. Mr. Gerstel currently serves as a director of YEDA Research and Development Company Ltd., the technology transfer company for the Weizmann Institute of Science and is also a member of the Board of Governors and the executive committee of the Weizmann Institute of Science and the Board of Governors of the Hebrew University of Jerusalem and the Board of the Clore Scholars Program. Prior to relocating to Israel in 1994, Mr. Gerstel was the Co-Chairman and CEO of ALZA Corporation, a U.S. pharmaceutical company specializing in advanced drug delivery (sold to Johnson & Johnson).

      Mr. Gerstel holds an M.B.A. degree from Stanford Graduate School of Business and a B.Sc. from Yale University.

    • Ms. Sarit Firon

      Board Member

      Ms. Sarit Firon has served as a director of Evogene since 2016. Ms. Firon is the Co-Founder & Managing Partner of Team8 Capital, the new investment vehicle of the Team8 group. Prior to that Ms. Firon was the Managing Partner of Cerca Partners, a Venture Capital, co-investment fund. Previously, Ms. Firon was the Chief Executive Officer of Extreme Reality (XTR3D), a company that provides real time software-based, 3D motion capture technology, using a single standard webcam. Prior to her role at Extreme Reality (XTR3D), Ms. Firon held roles as Chief Financial Officer at each of Kenshoo, MediaMind (NSDQ: MDMD, acquired by DG corp.), OLIVE SOFTWARE, P-CUBE (acquired by Cisco) and RADCOM, LTD. (NSDQ: RDCM). Ms. Firon serves as the Chairperson of myThings, a global leader in customized programmatic ad solutions, which runs personalized retargeting campaigns on desktop, mobile and Facebook, since July 2015. Ms. Firon also holds other board positions at DTORAMA and Protected Media.

      Ms. Firon holds a Bachelor’s degree in accounting and economics, and a Diploma in Accounting Advanced Studies, both from Tel Aviv University.

    • Mr. Ziv Kop

      Board Member

      Mr. Ziv Kop has served as Evogene director since 2014. Mr. Kop currently serves as Managing Partner at OG Tech Partners, a single LP VC backed by Eyal Ofer, supporting tech companies early in their growth stage.

      Prior to OG, , Mr. Kop was a Partner at Innovation Endeavors (Marker), an early and growth stage VC, a Board Member and COO at Outbrain and a Managing Partner at Glenrock Israel where he managed a portfolio of growth companies in the fields of advanced technologies and healthcare, and served on the board of more than ten private and public companies. Prior to his role at GlenRock, Mr. Kop served as Chief Executive Officer of POC Management Consulting, a leading Israeli consultancy in the field of strategic planning.

      During the past 17 years Mr. Kop has been an investor in Mobileye (NYSE), Outbrain, Quigo (AOL), Bluevine, Lendbuzz, VGames, Dynamic Yield (McDonald’s), Kamada (NASDAQ), Evogene (NASDAQ), Rainbow Medical among others.

      Mr. Kop holds an LL.B. and an MBA from Tel Aviv University Law School and Business School and is a graduate of INSEAD’s Young Managers Program. Mr. Kop served for six years in the Israeli Navy as an officer (“Chovel”) and a fleet and patrol boat commander.

    • Dr. Adrian Percy

      Board Member

      Dr. Adrian Percy has served as Evogene director since February 2019. Dr. Percy serves on the board of directors of BioLumic, HiFidelity Genetics and Biotalys. He is a member of the science and technology boards of Terramera, Biotalys and Rothamsted Research. Dr. Percy currently serves as the CTO of UPL Ltd., is a venture partner with Finistere Ventures and frequently acts as an advisor to companies through his own consultancy company, Nomad Technology Consulting. Previously, Dr. Percy served as the head of research and development for the Crop Science division of Bayer as part of its executive committee. During his 16-year tenure at Bayer, he also led crop protection development activities for Bayer in North America and regulatory affairs activities across the entire division of Crop Science. Dr. Percy has held positions in the research and development departments of Rhone Poulenc, Aventis CropScience and Bayer in France, Germany and the United States.

      Dr. Percy earned a bachelor’s degree in pharmacology at the University of Liverpool, as well as a master’s degree in toxicology and a doctorate in biochemistry at the University of Birmingham.

    • Mr. Leon Recanati

      Board Member

      Mr. Leon Y. Recanati has served as Evogene director since 2005. Mr. Recanati has served as chairman and chief executive officer of GlenRock Israel Ltd., his private investment company, investing since 2003 in Venture Capital and private equity companies. Previously, Mr. Recanati was chief executive officer and/or chairman of IDB Holding Corporation; Clal Industries Ltd.; Azorim Investment Development and Construction Co Ltd.; Delek Israel Fuel Corporation; and Super-Sol Ltd. He also founded Clal Biotechnologies Industries Ltd., a biotechnology investment company operating in Israel.

      Mr. Recanati is a member of the board of directors of Kamada Ltd. ,of Rainbow Medical and active in education and health endeavors through several NGO’s  .

      Mr. Recanati holds an MBA from the Hebrew University of Jerusalem and Honorary Doctorates from the Technion Institute of Technology and Tel Aviv University.

    • Prof. Oded Shoseyov

      Board Member

      Prof. Oded Shoseyov has served as Evogene director since 2018. Prof. Shoseyov is the scientific founder of 15 companies, including: Futuragene Ltd., Collplant Ltd., Biobetter Ltd., GemmaCert Ltd., SP-Nano materials Ltd., Melodea Ltd., Valentis Nanotech. Ltd., Paulee CleanTec Ltd., Smart Resilin Ltd., Sensogenic Ltd., SavorEat Ltd, Daika, Ltd, Neswell Group Ltd and Karme Yosef Winery. Prof. Shoseyov is a faculty member of The Hebrew University of Jerusalem, where he conducts research in plant molecular biology protein engineering and nano-biotechnology. His group focus is on Bio-Inspired Nanocomposite materials. He has authored or co-authored more than 200 scientific publications and is the inventor or co-inventor of 65 patents. Prof. Shoseyov is a TED speaker and a co-owner and winemaker of BRAVDO winery. Prof. Shoseyov received the Outstanding Scientist Polak Award for 2002, the 1999 and 2010 Kay Award for Innovative and Applied Research, the 2012 Israel Prime Minister Citation for Entrepreneurship and Innovation, and the 2018 Presidential Award for his contribution to the Economy and Society of Israel.

      Prof. Shoseyov holds a BSc from the Hebrew University, MSc from the Hebrew University, and a Ph.D. from the Hebrew University.

    • Mr. Nir Nimrodi

      Special Advisor to the board

      Mr. Nir Nimrodi has served as Special Advisor to the Evogene board since 2020.
      Mr. Nimrodi brings 25 years of diverse international experience in both start-ups and large global businesses in the life science, pharmaceutical, and biotechnology industries.
      Mr. Nimrodi is the Chairman and CEO of Accellix Inc since June 2019. Accellix aims to set a new standard in QC of Cell and Gene Therapies.
      Prior to joining Accellix, Mr. Nimrodi served as the Chief Business Officer of Intrexon Corporation, a leader in synthetic biology. At Intrexon, Mr. Nimrodi held direct responsibility for all of the commercial stage enterprises. Mr. Nimrodi has led the transformation of Intrexon from an R&D organization to one with multiple products in the market, each with the potential of generating hundreds of millions of dollars annually.
      Prior to Intrexon, Mr. Nimrodi has held positions with Life Technologies, Proneuron Biotechnologies, Mindsense Biosystems and Teva Pharmaceuticals.
      Mr. Nimrodi holds a BA in Economics and an MBA from the Tel Aviv University.

    • Prof. Avraham Levy, Chairman of the scientific advisory board

      Prof. Avraham Levy is the Head of the Plant Science Department of the Weizmann Institute of Science in Rehovot, Israel. Prof. Levy heads a laboratory studying mechanisms that contribute to the accelerated evolution of plant genomes, such as transposons, DNA damages, DNA recombination and genome duplications. He works on wheat, Arabidopsis tomato and budding yeast. Prof. Levy is the president of the Genetic Society of Israel, he served as the chairman of the Israeli Graminae consortium and on several national and international granting agencies panels. He is an ERC fellow and has lead scientific projects as coordinator for an EU consortium and for an Israeli Center of Research Excellence.

      Prof. Levy holds a B.Sc. and an M.Sc. degree from the Faculty of Agriculture of the Hebrew University of Jerusalem and a Ph.D. from the Department of Plant Genetics of the Weizmann Institute of Science. His post-doctoral research was done at Stanford University.

    • Prof. Naama Barkai

      Prof. Naama Barkai is a professor in the departments of Molecular Genetics and Physics of Complex Systems at the Weizmann Institute of Science in Rehovot, Israel and a member of of the European Molecular Biology Organization (EMBO), the European Bioinformatics Institute (EBI), the ERC Starting Grant evaluation panel, the European Molecular Biology Laboratory (EMBL), Academia Europaea, and of the Israel Academy of Sciences and Humanities.

      Prof. Naama Barkai received her PhD in Theoretical Physics in 1995 from the Hebrew University where she Graduated Summa Cum Laude in the studies of Statistical Mechanicsof Learning“. Her Post-Doctoral Fellow at the Physics Department, Princeton University in Princeton, New Jersey focused on Theoretical Study of Biochemical Networks.

      Prof. Barkai lab research is focused at the interface between mathematics and biology and understanding the biological constraints that are imposed on a particular system, and the impact of those constraints on the structural design of the network while developing novel solutions for fundamental biological problems such as nutrient homeostasis systems  and the organization of the cellular transcription programs.

  • As part of Evogene’s commitment to contribute to the community, the company sees great value in its involvement and its employees’ involvement in the community, with a focuse on populations in-need.

    Evogene’s social involvement in the community is through volunteering activities with the ‘ALEH’ association and with ‘AMCHA’- Rehovot.

    ‘ALEH’ provides state-of-the-art medical, educational and rehabilitative care in ALEH’s four facilities for 750 children with complex disabilities. ‘AMCHA’- Rehovot is the largest provider of mental health and social support services for Holocaust survivors in Israel.

    The cooperation includes integration of individuals from these organizations in the company’s on-going operation.

    Additionally, company employees volunteer in food collection, packaging and distribution, during the holidays, in cooperation with ‘Hod Israel’, a community charity organization, and ‘Latet’, an Israeli humanitarian aid organization to for populations in-need.